AcelRx Pharmaceuticals Reports First Quarter 2011 Financial Results

Thursday, May 12, 2011 General News
Email Print This Page Comment
Font : A-A+

Initiation of Phase 3 Trial for Lead Product Candidate ARX-01 On Track for Second Half of 2011

Statements of Operations

(in thousands, except share and per share data)

Three Months Ended March 31,

2011

2010

Operating Expenses:

Research and development

$1,946

$2,761

General and administrative

1,589

672

Total operating expenses

$3,535

$3,433

Loss from operations

($3,535)

($3,433)

Net interest and other income (expense), net

331

(248)

Net loss

($3,204)

($3,681)

Net loss per share of common stock, basic and diluted

($0.30)

($5.85)

Shares used in computing net loss per share of common stock, basic and diluted

10,742,182

629,006



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook